Table 1 Sociodemographic and clinicopathological characteristics among study groups
Variables | Prostate RT group n = 34 (54%) | Control group n = 29 (46%) | P-value |
|---|---|---|---|
Age (years) < 65 | 10 (29.4%) | 4 (13.8%) | 0.224 f |
> 65 | 24 (70.6%) | 25 (86.2%) | |
Median (IQR) | 68 (64–72) | 73 (68.5–79.5) | |
Marital status Married | 24 (70.6%) | 14 (48.3%) | 0.068 f |
Single | 10 (29.4%) | 15 (51.7%) | |
Residence Rural | 10 (29.4%) | 11 (37.9%) | 0.478 |
Urban | 24 (70.6%) | 18 (62.1%) | |
Histopathological variant Acinar adenocarcinoma | 32 (94.1%) | 24 (82.8%) | 0.233 f |
Others | 2 (5.9%) | 5 (17.2%) | |
GS ≤ 7 | 12 (35.3%) | 4 (13.8%) | 0.081 f |
8–10 | 22 (64.7%) | 25 (86.2%) | |
T Stage T2 | 13 (38.2%) | 8 (27.6%) | 0.371 |
T ≥ 3 | 21 (61.8%) | 21 (72.4%) | |
N Stage N0 | 17 (50%) | 22 (75.9%) | 0.035* |
N+ | 17 (50%) | 7 (24.1%) | |
Site of metastases Bones | 23 (67.6%) | 21 (72.4%) | 0.628 f |
Lungs | 2 (5.9%) | ||
> 1 site | 9 (26.5%) | 8 (27.6%) | |
Metastatic burden High metastatic burden | 18 (52.9%) | 22 (75.9%) | 0.060 |
Low metastatic burden | 16 (47.1%) | 7 (24.1%) | |
Timing of Metastases Synchronous | 27 (79.4%) | 27 (93.1%) | 0.160 f |
Metachronous | 7 (20.6%) | 2 (6.9%) | |
Performance status | |||
≤ 1 | 25 (73.5%) | 17 (58.6%) | 0.211 |
2 | 9 (26.5%) | 12 (41.4%) | |
Prior ADT Duration, median (IQR) | 4.25 (2.5-9) | 2.8 (1.9-8) | 0.073 |
GnRH agonist only | 3 (8.8%) | 5 (17.2%) | 0.453 f |
Bicalutamide only | 6 (17.6%) | 3 (10.3%) | 0.488 f |
Both | 25 (73.5%) | 21 (72.4%) | 0.921 |
Response to ADT Castration naïve/sensitive | 24 (70.6%) | 19 (65.5%) | 0.666 |
Castration resistant | 10 (29.4%) | 10 (34.5%) | |
Docetaxel | 7 (20.6%) | 9 (31%) | 0.342 |
Abiraterone acetate | 10 (29.4%) | 4 (13.8%) | 0.224 f |
Enzalutamide | 2 (5.9%) | 1 (3.4%) | 1.000 f |
Palliative RT | 9 (26.5%) | 25 (86.2%) | < 0.001* |
Comorbidities* | 22 (64.7%) | 19 (65.5%) | 0.946 |